Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
In a post hoc analysis of a phase 1 trial, nivolumab treatment was associated with long-term survival in a subset of patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer.
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Within the first 2 lines of treatment, patients with metastatic renal cell carcinoma who remain on a drug for at least 3 months have longer overall survival than those who do not, a study found.
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
Use of specific immunomodulatory agents is proposed for those with specific corticosteroid-refractory immune-related cutaneous adverse events (ircAEs) based on results of a retrospective analysis.
